DIA444.52+2.14 0.48%
SPX6,263.26+37.74 0.61%
IXIC20,611.34+192.87 0.95%

Biodesix To Present New INSIGHT Study Data At ASCO 2025 Showing VeriStrat Test Predicts Improved Survival With Chemoimmunotherapy Over Immunotherapy Alone In PD-L1 ≥50% Metastatic NSCLC Patients With Poor Immune Classifier

Benzinga·05/22/2025 21:27:48
Listen to the news

Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The presentation titled "Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC" features data from the INSIGHT study (NCT03289780) which enrolled greater than 5,000 patients with non-small cell lung cancer (NSCLC). The data will be presented by Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone's Perlmutter Cancer Center.

The VeriStrat test measures a patient's immune response to lung cancer and is reported as either Host Immune Classifier Hot (VeriStrat Good) or Host Immune Classifier Cold (VeriStrat Poor). The new data strengthens prior findings and demonstrates statistically significant improvement of overall survival (OS) in patients with a VeriStrat Poor result when receiving immunotherapy combined with chemotherapy versus immunotherapy as a single agent. Notably, the two-year survival rate was more than three times higher in patients receiving immunotherapy plus chemotherapy compared to those who received immunotherapy alone. Additionally, patients with a VeriStrat Good result had comparable survival when receiving either treatment regimen.

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.